Laura Sánchez-Vela
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Laura Sánchez-Vela has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Dou
Department of Ophthalmology, Vall d’Hebron University Hospital, 08035 Barcelona, Spain
2 shared publications - Jaume Rigo-Quera
Department of Ophthalmology, Vall d’Hebron University Hospital, 08035 Barcelona, Spain
2 shared publications - Manuel Amilburu
Department of Ophthalmology, Vall d’Hebron University Hospital, 08035 Barcelona, Spain
2 shared publications - Marta Castany
Vall d'Hebron University Hospital, Department of Ophthalmology, Barcelona, Spain
2 shared publications - Olivia Pujol-Carreras
Department of Ophthalmology, Vall d’Hebron University Hospital, 08035 Barcelona, Spain
2 shared publications - Yann Bertolani
Ophthalmology Department, Vall d'Hebron University Hospital, Passeig de la Vall d'Hebron 129, 08035 Barcelona, Spain
2 shared publications
Latest Publications
- Open Access
- 19 May 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (10) , 3545
Efficacy and Safety of Open-Conjunctiva Ab Externo 63 µm vs. 45 µm XEN® Gel Stent in Glaucoma Surgery: One-Year Follow-Up
Background: To compare the efficacy and safety of the XEN® 63 µm and 45 µm devices with the ab externo open conjunctiva with a 30G needle approach. Methods: A retrospective, non-randomized and single-center study was conducted. Consecutive eyes undergoing a XEN® 63 µm implant were compared with a matched cohort of cases with a XEN® 45 µm implant. Standalone and combined procedures with phacoemulsification were included. Results: A total of 28 XEN® 45 µm and 28 XEN® 63 µm were included. Complete surgical success was achieved in 17 cases (60.7%) in the 45 µm group and in 20 cases (71.4%) in the 63 µm group, with no statistical differences. One year after the surgery, the mean IOP was 13.8 ± 3.3 mmHg for the 45 µm group and 12.4 ± 4.2 mmHg for the 63 µm group (p-value > 0.05). Likewise, the use of glaucoma medication was lowered in the 63 µm device (0.32 ± 0.87) compared to the 45 µm device (0.39 ± 0.86), with no statistical significance. Postoperative hypotony was more frequent in the 63 µm device (39.3%) than in the 45 µm group (28.6%), with no statistical differences. However, hypotony-associated complications (including choroidal detachment, hypotony keratopathy, and hypotony maculopathy) were significantly higher in the 63 µm group (p = 0.011). Conclusions: Although the XEN® 63 µm may offer a greater IOP-lowering effect with better complete surgical success, no significant differences were detected compared to the 45 µm device. Hypotony-related complications were higher in the XEN 63 µm, although most of them resolved with conservative management.
- 19 May 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (10) , 3545
Open AccessEfficacy and Safety of Open-Conjunctiva Ab Externo 63 µm vs. 45 µm XEN® Gel Stent in Glaucoma Surgery: One-Year Follow-Up
Background: To compare the efficacy and safety of the XEN® 63 µm and 45 µm devices with the ab externo open conjunctiva with a 30G needle approach. Methods: A retrospective, non-randomized and single-center study was conducted. Consecutive eyes undergoing a XEN® 63 µm implant were compared with a matched cohort of cases with a XEN® 45 µm implant. Standalone and combined procedures with phacoemulsification were included. Results: A total of 28 XEN® 45 µm and 28 XEN® 63 µm were included. Complete surgical success was achieved in 17 cases (60.7%) in the 45 µm group and in 20 cases (71.4%) in the 63 µm group, with no statistical differences. One year after the surgery, the mean IOP was 13.8 ± 3.3 mmHg for the 45 µm group and 12.4 ± 4.2 mmHg for the 63 µm group (p-value > 0.05). Likewise, the use of glaucoma medication was lowered in the 63 µm device (0.32 ± 0.87) compared to the 45 µm device (0.39 ± 0.86), with no statistical significance. Postoperative hypotony was more frequent in the 63 µm device (39.3%) than in the 45 µm group (28.6%), with no statistical differences. However, hypotony-associated complications (including choroidal detachment, hypotony keratopathy, and hypotony maculopathy) were significantly higher in the 63 µm group (p = 0.011). Conclusions: Although the XEN® 63 µm may offer a greater IOP-lowering effect with better complete surgical success, no significant differences were detected compared to the 45 µm device. Hypotony-related complications were higher in the XEN 63 µm, although most of them resolved with conservative management.
- Open Access
- 5 May 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (9)
Efficacy and Safety of Ab Externo Open Conjunctiva XEN® 63 µm Implantation with a 30G Needle Scleral Tract in Primary Open-Angle Glaucoma
Background: This study aimed to assess the efficacy and safety of the 30G needle mediated ab externo open conjunctiva approach for the XEN 63 µm implant in primary open-angle glaucoma. Methods: A retrospective and non-randomized study was conducted on consecutive cases of medically refractory primary open-angle glaucoma treated with standalone ab externo open conjunctiva XEN® 63 µm (North Chicago, Illinois) with one-year follow-up. Results: Twenty-two eyes were included. The mean preoperative intraocular pressure was 21.9 ± 7.2 mmHg, and the mean number of glaucoma medications was 2.4 ± 0.9. All patients underwent mitomycin 0.02% application for 2 min, and Healaflow® (MedicalMix, Spain), was implanted in 11 cases (50%). Complete surgical success was achieved in 14 cases (63.6%). No statistical differences in complete surgical success were noted based on the use of Healaflow®. A significant reduction in intraocular pressure (11.8 ± 3.4 mmHg) and in the number of hypotensive medications (0.2 ± 0.5 mmHg) was observed 1 year after the procedure. Transient hypotony was detected in 31.8% of cases. Complications secondary to hypotony included four cases of serous choroidal detachment and one case of localized hemorrhagic choroidal detachment, the latter associated with hypotonic keratopathy and hypotonic maculopathy. All these complications evolved favorably with conservative management and adjusted topical treatment. Conclusions: This study highlights the efficacy and safety of this approach for the XEN 63 µm implant in medically refractory primary open-angle glaucoma.
- 5 May 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (9)
Open AccessEfficacy and Safety of Ab Externo Open Conjunctiva XEN® 63 µm Implantation with a 30G Needle Scleral Tract in Primary Open-Angle Glaucoma
Background: This study aimed to assess the efficacy and safety of the 30G needle mediated ab externo open conjunctiva approach for the XEN 63 µm implant in primary open-angle glaucoma. Methods: A retrospective and non-randomized study was conducted on consecutive cases of medically refractory primary open-angle glaucoma treated with standalone ab externo open conjunctiva XEN® 63 µm (North Chicago, Illinois) with one-year follow-up. Results: Twenty-two eyes were included. The mean preoperative intraocular pressure was 21.9 ± 7.2 mmHg, and the mean number of glaucoma medications was 2.4 ± 0.9. All patients underwent mitomycin 0.02% application for 2 min, and Healaflow® (MedicalMix, Spain), was implanted in 11 cases (50%). Complete surgical success was achieved in 14 cases (63.6%). No statistical differences in complete surgical success were noted based on the use of Healaflow®. A significant reduction in intraocular pressure (11.8 ± 3.4 mmHg) and in the number of hypotensive medications (0.2 ± 0.5 mmHg) was observed 1 year after the procedure. Transient hypotony was detected in 31.8% of cases. Complications secondary to hypotony included four cases of serous choroidal detachment and one case of localized hemorrhagic choroidal detachment, the latter associated with hypotonic keratopathy and hypotonic maculopathy. All these complications evolved favorably with conservative management and adjusted topical treatment. Conclusions: This study highlights the efficacy and safety of this approach for the XEN 63 µm implant in medically refractory primary open-angle glaucoma.